Elacytarabine Failure Leaves Clavis Scrambling For Buyer
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III failure of Clavis’ AML candidate elacytarabine likely spells the end of the road for the Norwegian company and its lipid vector technology approach to drug development. Clavis is aiming to find a buyer or merger option or considering closing its doors.